SecurityAZN / AstraZeneca Plc
InstitutionCrawford Investment Counsel Inc
Shares1,726,468
Value $ 60,616,000
Related 046353AB4 / Astrazeneca 5.9% Senior Notes 9/15/17
046353AF5 / Astrazeneca Plc 1.95% 09/18/19
046353AG3 / Astrazeneca Plc 4.00% 09/18/42
046353AA6 / Astrazeneca Plc 5.40% Notes 06/01/2014
046353AD0 / Astrazeneca Plc 6.45% Senior Notes 9/15/37
98934KAB6 / Zeneca Wilmington Inc Guaranteed Debentures 7% 11/15/23

Crawford Investment Counsel Inc reports 6.84% increase in ownership of AZN / AstraZeneca Plc

August 14, 2018 - Crawford Investment Counsel Inc has filed a 13F-HR form disclosing ownership of 1,726,468 shares of AstraZeneca Plc (NYSE:AZN) with total holdings valued at $60,616,000 USD as of June 30, 2018. Crawford Investment Counsel Inc had filed a previous 13F-HR on May 15, 2018 disclosing 1,615,981 shares of AstraZeneca Plc at a value of $56,511,000 USD. This represents a change in shares of 6.84 percent and a change in value of 7.26 percent during the quarter.

Other investors with positions similar to Crawford Investment Counsel Inc include Invesco Ltd., Capital Bank & Trust Co, Bank Of Montreal /can/, Cullen Capital Management, LLC, Canada Pension Plan Investment Board, and Capital Guardian Trust Co.

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 35.04 1,726,468 6.84 60,616 7.26 3,871 234 0.41
2018-03-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 34.84 1,615,981 168.50 56,511 170.58 35,327 299 1.43
2017-12-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 34.29 601,862 1.73 20,885 4.19 350 490 2.44
2017-09-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 33.98 591,653 36.69 20,045 35.84 5,397 -108 -0.73
2017-06-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 32.61 432,858 -21.88 14,756 -14.48 -3,955 1,456 8.44
2017-03-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 29.23 554,108 10.61 17,255 26.08 1,553 2,016 14.73
2016-12-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 30.09 500,964 6.53 13,686 -11.43 925 -2,691 -17.41
2016-09-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 31.53 470,235 21.87 15,452 32.65 2,660 1,143 9.81
2016-06-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 29.18 385,845 27.90 11,649 37.13 2,456 698 8.22
2016-03-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 31.06 301,675 2,514.17 8,495 2,067.09 9,013 -910 -232.09
2015-12-31 13F-HR ASTRAZENECA COM 046353108 32.89 11,540 -13.62 392 -7.76 -60 27 6.32
2015-09-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 47.77 13,360 113.93 425 6.78 340 -313 -78.62
2015-06-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 66.08 6,245 -84.56 398 -85.62 -2,260 -110 -3.96
2015-03-31 13F-HR Astrazeneca PLC ADR SPONSORED ADR 046353108 69.40 40,455 1.57 2,768 -1.25 43 -78 -2.80
2014-12-31 13F-HR ASTRAZENECA COM 046353108 70.91 39,830 -6.45 2,803 -7.86 -195 -44 -1.46
2014-09-30 13F-HR Astrazeneca PLC ADR COM 046353108 72.87 42,575 79.83 3,042 72.94 1,377 -94 -5.36
2014-06-30 13F-HR Astrazeneca PLC ADR COM 046353108 23,675 1,759

Related SEC Filings

AZN / AstraZeneca Plc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o

AZN / AstraZeneca Plc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o

AZN / AstraZeneca Plc / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
gb0009895292_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) ASTRAZENECA PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B01DCL2 -------------------------------------------------------- (SEDOL Number) December 31, 2017 --------------------------------------------------------

AZN / AstraZeneca Plc / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
gb0009895292_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) ASTRAZENECA PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B01DCL2 -------------------------------------------------------- (SEDOL Number) December 31, 2017 --------------------------------------------------------

AstraZeneca SEC SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares)

2017-02-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 30, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o (0-1)

Related News Stories

3 Large-Cap Pharma Stocks Performing Better Than Industry

2018-10-12 zacks
The Zacks Large-Cap Pharma industry, a 14 medical stock group, has gained 5.4% in the year so far. This industry also features among the top 9% of the 256 Zacks-ranked industries. (9-0)

J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion

2018-10-12 zacks
Janssen, a subsidiary of Johnson & Johnson (JNJ - Free Report) , announced that the FDA has approved the label expansion of its blood thinner, Xarelto. The drug is now approved for reduction in risk of major cardiovascular (“CV”) events including CV death, myocardial infarction (“MI”) and stroke, in patients with chronic coronary or peripheral artery disease (CAD/PAD). (16-0)

PhaseBio IPO: Data To Be Released In 2018 And 2020

2018-10-12 seekingalpha
PhaseBio is a clinical-stage biopharmaceutical company developing treatments for orphan diseases. With a specialization on the cardiopulmonary space, the company has two product candidates, PB2452 and PB1046. (3-0)

Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts

2018-10-11 zacks
On Oct 10, we issued an updated research report on Merrimack Pharmaceuticals, Inc. (MACK - Free Report) . (16-0)

Tencent reaches into London’s tech hub for Parkinson’s partner

2018-10-09 thestar.com.my
Digital analysis: Tencent Holdings Ltd is teaming with closely held Medopad Ltd to develop a system to remotely monitor patients with the severe movement disorder. — Reuters (4-0)



CUSIP: 046353108